Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
54
CANC Quote, Financials, Valuation and Earnings
Last price:
$25.92
Seasonality move
:
1.76%
Day range:
$25.62 - $26.21
52-week range:
$20.10 - $30.11
Dividend yield:
1.94%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
5.4K
Avg. volume:
27.9K
1-year change:
-9.98%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
HRTS
Tema Heart & Health ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
$25.81 | -- | -- | -- | $0.73 | 1.94% | -- |
|
AGNG
Global X Aging Population ETF
|
$32.12 | -- | -- | -- | $0.14 | 0.9% | -- |
|
BMED
iShares Health Innovation Active ETF
|
$25.10 | -- | -- | -- | $0.01 | 0% | -- |
|
HRTS
Tema Heart & Health ETF
|
$28.84 | -- | -- | -- | $0.47 | 0.5% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$28.75 | -- | -- | -- | $0.00 | 0% | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
$23.15 | -- | -- | -- | $0.26 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | 0.844 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.588 | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | 0.902 | -- | -- |
|
HRTS
Tema Heart & Health ETF
|
-- | 0.652 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.335 | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | 0.615 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
HRTS
Tema Heart & Health ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | -- | -- | -- | -- | -- |
Tema Oncology ETF vs. Competitors
-
Which has Higher Returns CANC or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About CANC or AGNG?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema Oncology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is CANC or AGNG More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.45%.
-
Which is a Better Dividend Stock CANC or AGNG?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 1.94%. Global X Aging Population ETF offers a yield of 0.9% to investors and pays a quarterly dividend of $0.14 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or AGNG?
Tema Oncology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns CANC or BMED?
iShares Health Innovation Active ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat iShares Health Innovation Active ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- BMEDiShares Health Innovation Active ETF-- -- -- -
What do Analysts Say About CANC or BMED?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Health Innovation Active ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than iShares Health Innovation Active ETF, analysts believe Tema Oncology ETF is more attractive than iShares Health Innovation Active ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 BMEDiShares Health Innovation Active ETF0 0 0 -
Is CANC or BMED More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Health Innovation Active ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or BMED?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 1.94%. iShares Health Innovation Active ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Tema Oncology ETF pays -- of its earnings as a dividend. iShares Health Innovation Active ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or BMED?
Tema Oncology ETF quarterly revenues are --, which are smaller than iShares Health Innovation Active ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than iShares Health Innovation Active ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while iShares Health Innovation Active ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for iShares Health Innovation Active ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- BMEDiShares Health Innovation Active ETF-- -- -- --
-
Which has Higher Returns CANC or HRTS?
Tema Heart & Health ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema Heart & Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- HRTSTema Heart & Health ETF-- -- -- -
What do Analysts Say About CANC or HRTS?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Heart & Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema Heart & Health ETF, analysts believe Tema Oncology ETF is more attractive than Tema Heart & Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 HRTSTema Heart & Health ETF0 0 0 -
Is CANC or HRTS More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Heart & Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or HRTS?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 1.94%. Tema Heart & Health ETF offers a yield of 0.5% to investors and pays a quarterly dividend of $0.47 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema Heart & Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or HRTS?
Tema Oncology ETF quarterly revenues are --, which are smaller than Tema Heart & Health ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema Heart & Health ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema Heart & Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema Heart & Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- HRTSTema Heart & Health ETF-- -- -- --
-
Which has Higher Returns CANC or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About CANC or HTEC?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Tema Oncology ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is CANC or HTEC More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.148, suggesting its more volatile than the S&P 500 by 14.776%.
-
Which is a Better Dividend Stock CANC or HTEC?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 1.94%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tema Oncology ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or HTEC?
Tema Oncology ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns CANC or MNTL?
Tema Neuroscience and Mental Health ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema Neuroscience and Mental Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- MNTLTema Neuroscience and Mental Health ETF-- -- -- -
What do Analysts Say About CANC or MNTL?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Neuroscience and Mental Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema Neuroscience and Mental Health ETF, analysts believe Tema Oncology ETF is more attractive than Tema Neuroscience and Mental Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 MNTLTema Neuroscience and Mental Health ETF0 0 0 -
Is CANC or MNTL More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Neuroscience and Mental Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or MNTL?
Tema Oncology ETF has a quarterly dividend of $0.73 per share corresponding to a yield of 1.94%. Tema Neuroscience and Mental Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.26 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema Neuroscience and Mental Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or MNTL?
Tema Oncology ETF quarterly revenues are --, which are smaller than Tema Neuroscience and Mental Health ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema Neuroscience and Mental Health ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema Neuroscience and Mental Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema Neuroscience and Mental Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- MNTLTema Neuroscience and Mental Health ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
